Literature DB >> 29250155

Correlation of diffusion tensor imaging parameters and Gleason scores of prostate cancer.

Weizhong Tian1, Ji Zhang1, Fangzheng Tian1, Junkang Shen2, Tianli Niu3, Guohua He4, Hong Yu5.   

Abstract

The aim of the present study was to explore the association between the parameters of diffusion tensor imaging (DTI), including fractional anisotropy (FA) values, apparent diffusion coefficient (ADC) values and the diffusion tensor tractography (DTT) map, with the Gleason score of prostate cancer (PCa). A retrospective study of 50 cases of PCa confirmed by biopsy or surgical pathology was performed. Conventional magnetic resonance imaging and DTI scans were conducted in these cases. The 50 cases of PCa were divided into three groups, including low, intermediate and high grade, according to the Gleason score. Post-DTI processing was performed using Neuro 3D software, in order to measure the FA and ADC values, and map the prostate fibers. Differences in FA and ADC values among the various PCa groups were examined using analysis of variance, while the correlation of FA and ADC values with the Gleason score was studied using Pearson correlation analysis. The obtained DTT map clearly demonstrated the spatial structure of the prostate fibers. The fibers of the cancer area were dense without interruption in the low-grade group, sparse and disordered in the intermediate-grade group, and were disordered, sparse or even absent in the high-grade group. The FA values were 0.284±0.313, 0.293±0.347 and 0.369±0.347, respectively, with statistically significant differences observed among the three groups (F=234.533; P<0.05) and between each group (P<0.05). In addition, the FA value of PCa was positively correlated with the Gleason score (r=0.884; P<0.05). The ADC values of the low-, intermediate- and high-grade groups were 1.070±0.072×10-3, 0.961±0.081×10-3 and 0.821±0.048×10-3, respectively, which demonstrated statistically significant differences among the three groups (F=49.987; P<0.05) and between each group (P<0.05). Furthermore, the ADC values of PCa were negatively correlated with Gleason score (r=-0.810; P<0.05). In conclusion, there was an association between DTI parameters and Gleason score, which may be used to evaluate the grading and prognosis of PCa.

Entities:  

Keywords:  Gleason score; apparent diffusion coefficient; diffusion tensor imaging; diffusion tensor tractography; fractional anisotropy; magnetic resonance imaging; prostate cancer

Year:  2017        PMID: 29250155      PMCID: PMC5729705          DOI: 10.3892/etm.2017.5363

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  18 in total

Review 1.  Diffusion tensor imaging: concepts and applications.

Authors:  D Le Bihan; J F Mangin; C Poupon; C A Clark; S Pappata; N Molko; H Chabriat
Journal:  J Magn Reson Imaging       Date:  2001-04       Impact factor: 4.813

2.  In vivo diffusion tensor imaging of the human prostate.

Authors:  Shantanu Sinha; Usha Sinha
Journal:  Magn Reson Med       Date:  2004-09       Impact factor: 4.668

3.  DWI-associated entire-tumor histogram analysis for the differentiation of low-grade prostate cancer from intermediate-high-grade prostate cancer.

Authors:  Chen-Jiang Wu; Qing Wang; Hai Li; Xiao-Ning Wang; Xi-Sheng Liu; Hai-Bin Shi; Yu-Dong Zhang
Journal:  Abdom Imaging       Date:  2015-10

4.  Diffusion tensor imaging of the normal prostate at 3 Tesla.

Authors:  Bengi Gürses; Neslihan Kabakci; Arzu Kovanlikaya; Zeynep Firat; Ali Bayram; Aziz Müfit Uluğ; Aziz Müfit Uluo; Ilhami Kovanlikaya
Journal:  Eur Radiol       Date:  2007-10-25       Impact factor: 5.315

5.  Correlation of gleason scores with magnetic resonance diffusion tensor imaging in peripheral zone prostate cancer.

Authors:  Liang Li; Daniel J A Margolis; Ming Deng; Jie Cai; Ling Yuan; Zhaoyan Feng; Xiangde Min; Zhiquan Hu; Daoyu Hu; Jihong Liu; Liang Wang
Journal:  J Magn Reson Imaging       Date:  2014-12-03       Impact factor: 4.813

6.  Determination of three-dimensional muscle architectures: validation of the DTI-based fiber tractography method by manual digitization.

Authors:  P Schenk; T Siebert; P Hiepe; D Güllmar; J R Reichenbach; C Wick; R Blickhan; M Böl
Journal:  J Anat       Date:  2013-05-16       Impact factor: 2.610

7.  Diagnostic utility of diffusion tensor imaging in differentiating glioblastomas from brain metastases.

Authors:  S Wang; S J Kim; H Poptani; J H Woo; S Mohan; R Jin; M R Voluck; D M O'Rourke; R L Wolf; E R Melhem; S Kim
Journal:  AJNR Am J Neuroradiol       Date:  2014-02-06       Impact factor: 3.825

8.  Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy.

Authors:  Courtney A Woodfield; Glenn A Tung; David J Grand; John A Pezzullo; Jason T Machan; Joseph F Renzulli
Journal:  AJR Am J Roentgenol       Date:  2010-04       Impact factor: 3.959

9.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

10.  ADC value and diffusion tensor imaging of prostate cancer: changes in carbon-ion radiotherapy.

Authors:  Yukihisa Takayama; Riwa Kishimoto; Shouhei Hanaoka; Hiroi Nonaka; Susumu Kandatsu; Hiroshi Tsuji; Hirohiko Tsujii; Hiroo Ikehira; Takayuki Obata
Journal:  J Magn Reson Imaging       Date:  2008-06       Impact factor: 4.813

View more
  2 in total

1.  Discrimination between clinical significant and insignificant prostate cancer with apparent diffusion coefficient - a systematic review and meta analysis.

Authors:  Hans-Jonas Meyer; Andreas Wienke; Alexey Surov
Journal:  BMC Cancer       Date:  2020-05-27       Impact factor: 4.430

2.  Application of diffusion tensor tractography in the surgical treatment of brain tumors located in functional areas.

Authors:  Hongliang Zhang; Yugong Feng; Lei Cheng; Jie Liu; Huanting Li; Hong Jiang
Journal:  Oncol Lett       Date:  2019-11-29       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.